Astrana Health: Market Overreaction to CMS Risk-Adjustment Proposal Creates a Buy Opportunity

William Blair analyst Ryan Daniels has maintained their bullish stance on ASTH stock, giving a Buy rating on January 16.

Ryan Daniels has given his Buy rating due to a combination of factors that suggest the recent pullback in Astrana Health’s stock is excessive relative to its actual risk exposure. He notes that while the CMS 2027 Advance Notice for Medicare Advantage was softer than investors anticipated, the market reaction in Astrana’s shares was disproportionately negative compared with peers that are more heavily dependent on Medicare Advantage revenue. In his view, this dislocation has created an appealing entry opportunity for investors with a longer time horizon.

In addition, Daniels emphasizes that Astrana’s business model relies on in-person, encounter-based patient interactions rather than the audio-only visits and unlinked chart reviews that CMS is targeting for tighter risk-adjustment rules. Because of this, he believes the proposed risk model changes should have only a minimal impact on Astrana’s financials, especially relative to the broader MA market. Given the company’s more limited Medicare exposure versus pure-play MA operators and its operational approach that is already aligned with CMS’s preferred documentation standards, he sees the sell-off as out of line with fundamentals and supports a Buy recommendation.